Accuray (ARAY) Set to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY - Get Free Report) will be issuing its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Accuray has set its FY 2025 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. The company had revenue of $134.29 million for the quarter, compared to the consensus estimate of $122.80 million. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. During the same period in the prior year, the firm posted ($0.03) EPS. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Stock Performance

NASDAQ:ARAY traded up $0.02 during trading hours on Wednesday, reaching $1.88. 410,409 shares of the company's stock were exchanged, compared to its average volume of 657,160. Accuray has a 1-year low of $1.40 and a 1-year high of $3.05. The company has a quick ratio of 0.95, a current ratio of 1.66 and a debt-to-equity ratio of 3.65. The firm has a market capitalization of $186.58 million, a price-to-earnings ratio of -8.45 and a beta of 1.39. The company has a 50-day moving average of $1.94 and a 200 day moving average of $1.85.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.